Biotech entity

PSMA

Technology

clinical-trial is the sole category represented across all 1 tracked stories. PSMA is most often covered alongside 177Lu rhPSMA‑10.1 Injection, which appears in 1 of these 1 story. PSMA appears in 1 tracked Biotech story from July 27, 2026. The tracked stories average 2 original sources each.

Last mentioned: Mar 10, 2026

RSS updates
Share

Entity pulse

Recent coverage · PSMA

1 story
6 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about PSMA

clinical-trial is the sole category represented across all 1 tracked stories. PSMA is most often covered alongside 177Lu rhPSMA‑10.1 Injection, which appears in 1 of these 1 story. PSMA appears in 1 tracked Biotech story from July 27, 2026. The tracked stories average 2 original sources each.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 16 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering PSMA. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. First Participant Dosed

    Blue Earth Therapeutics and UCL announced initiation of the Phase 1 trial (NCT07414940) with first participant receiving Actinium (225Ac) rhPSMA-10.1 Injection.

Stories mentioning PSMA 1

PSMA is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.